Major milestone for Dewpoint with first development candidate announced

30 October 2024

Dewpoint Therapeutics, a US biotech focused on the application of biomolecular condensate biology, has announced the nomination of its first development candidate, DPTX3186.

This orally-administered small molecule condensate modulator (c-mod) inhibiting the oncogenic function of beta catenin, is being developed as a potential therapeutic agent for treatment of Wnt-driven cancers.

DPTX3186 was discovered using Dewpoint’s fully automated, AI/ML-enabled platform and proprietary chemical library. It is being developed in collaboration with Germany’s Evotec (FSE: EVT/Nasdaq: EVO).

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK